amyloid-β peptides

PPI-1019 is an APP (β-amyloid A4) inhibitor for the treatment of neurological disorders and the study of Alzheimer's disease (AD).

Edonerpic maleate (T-817 maleate) is a neurotrophic agent which can inhibit amyloid-β peptides (Aβ).

GRGDSPK acetate shows inhibitory activity against integrin-fibronectin binding and can be used in research on integrins in bone formation and resorption.

Dihydroergocristine mesylate (DHEC (mesylate))(DHEC mesylate) is the methanesulfonic acid salt of dihydroergocristine. It has been used as the for the symptomatic treatment of mental deterioration associated with cerebrovascular insufficiency and in peripheral vascular disease. Dihydroergocristine mesylate is a inhibitor of γ-secretase (GSI), , reduces the production of the Alzheimer's disease amyloid-β peptides, binds directly to γ-secretase and Nicastrin with equilibrium dissociation constants (Kd) of 25.7 nM and 9.8 μM, respectively[1]. It is also a component of ergoloid mesylate (codergocrine mesilate), a mixture of ergot alkaloid derivatives that is used as a vasodilator and has shown mild benefits in the treatment of vascular dementia. It has a role as a vasodilator agent, an alpha-adrenergic antagonist and a geroprotector. It contains a dihydroergocristine.

BuChE-IN-20 is a selective hBuChE inhibitor (IC50= 0.13 μM) with the ability to cross the blood-brain barrier (BBB). This compound, a derivative of L-Tryptophan, exhibits neuroprotective effects by inhibiting nitric oxide (NO) production and reducing reactive oxygen species (ROS) levels. It effectively suppresses the self-aggregation of amyloid-beta (Aβ) peptides and is applicable in Alzheimer's disease research.

AChE-IN-47 (compound g17) is an acetylcholinesterase (AChE) inhibitor with an IC50 of 0.24 μM. It prevents the self-aggregation of β-amyloid peptides and exhibits neuroprotective properties by effectively reducing the accumulation of intracellular reactive oxygen species (ROS).

BChE-IN-31 (Compound 14d) is a selective butyrylcholinesterase inhibitor with an IC50 value of 65 nM. It effectively inhibits the self-induced aggregation of neurotoxic amyloid-β (Aβ) peptides.

MAO-B-IN-48 is a selective inhibitor of MAO-B with an IC50 of 0.09 μM and Ki of 0.02 μM. It also demonstrates inhibitory activity against hBChE (IC50= 1.10 μM, Ki= 0.43 μM) and AChE (IC50= 0.56 μM, Ki= 0.14 μM). MAO-B-IN-48 disrupts the self-induced aggregation of toxic β-amyloid peptides and exhibits antioxidant properties, including DPPH radical scavenging, CUPRAC copper ion reduction, and superoxide anion scavenging. This compound is applicable in Alzheimer’s disease (AD) research.

BSBM6 is an inhibitor of Aβ aggregation and neuronal toxicity that acts by reversing the aggregation and toxicity of amyloid-β peptides.

(Rac)-Z-Phe-Phe-FMK (Cathepsin L-IN-2) is a cathepsin L inhibitor that inhibits the tendency of β-amyloid to induce apoptotic changes .

BMS-984923 is an orally available and blood-brain barrier permeable mGluR5 silencing allosteric modulator that inhibits β-amyloid oligomer-induced aberrant synaptic signaling, and can be used to study Alzheimer's disease.

Lecanemab (BAN-2401) is an IgG1 monoclonal antibody targeting soluble aggregated β-amyloid (Abeta) with activity against oligomers, protofibrils, and insoluble protofibrils, and may be useful in the study of Alzheimer's disease (AD)-induced mild cognitive impairment and mild AD dementia.

Phenserine tartrate ((-)-Eseroline phenylcarbamate) is a derivative of Physostigmine and functions as an efficient, non-competitive, long-acting, and selective inhibitor of acetylcholinesterase (AChE). This compound reduces the formation of amyloid precursor protein (APP) and β-amyloid peptides (Aβ), potentially improving cognitive abilities and alleviating the progression of Alzheimers disease.

PF-04382923 is a humanized IgG2Δa monoclonal antibody. It binds with high affinity to the free C-terminal region of amyloid β (Aβ) peptides Aβ1-40 and Aβ1-42. PF-04382923 is utilized in research concerning geographic atrophy (GA) associated with dry age-related macular degeneration (ARMD).

β-Amyloid (29-40) is a fragment of Amyloid-β peptide. Alzheimer's beta amyloid peptide (29-40/42) C-terminal fragments exhibit physical and chemical properties similar to fusion peptides of viral proteins, inducing liposome fusion in vitro.

Amyloid β Peptide (42-1)(human) acetate is the inactive form of Amyloid β Peptide (1-42). Amyloid β Peptide (42-1)(human) acetate is a 42-amino acid peptide which plays a key role in the pathogenesis of Alzheimer disease.

V-9-M cholecystokinin nonapeptideV-9-M cholecystokinin nonapeptide provides a structural basis and research tool for the design and screening of novel drug candidates, and is commonly used in drug discovery, drug synthesis, and related research.

(Val2)-Amyloid β-Protein (1-6) is a peptide identified through peptide screening, which is a research tool primarily employing immunoassays to gather active peptides. This method is applicable in studying protein interactions, conducting functional analyses, and screening antigen epitopes, particularly in the research and development of active molecules.

Amyloid β-Protein (1-24) is a peptide identified through peptide screening. This tool predominantly employs immunoassays to gather and analyze active peptides. Peptide screening is utilized in studies involving protein interactions, functional analysis, and epitope screening, particularly relevant in the research and development of active molecules.